2019. The second stage construction and rebranding project.

2019. The second stage construction and rebranding project.

Engineering system installation in the new manufacturing plant and finalisation of the rebranding process.

2017. The 80th Anniversary

2017. The 80th Anniversary

Samson Med celebrates its 80th anniversary. The new manufacturing plant construction process is in its active phase. Launch of numerous projects in R&D department on existing products and technologies modernization, partnerships with leading research institutes of Russian Federation.

2016. A project of strategic importance

2016. A project of strategic importance

Samson-Med becomes a resident of Saint-Petersburg Localization and Import Substitution Center. The project of the new Samson-Med manufacturing plant construction is recognized as strategic one for the city by the Saint-Petersburg Government.

2010. A new manufacturing plant and Pharmaceutical cluster

2010.  A new manufacturing plant and Pharmaceutical cluster

Samson-Med becomes a memeber of Saint-Petersburg Pharmaceutical cluster. An agreement on a new Samson-Med manufacturing plant construction signed by the Government of Saint-Petersburg.

1998. Launch of Samprost®

1998. Launch of Samprost®

Registration and start of production of Samprost® which became one of the first locally produced biologic drugs against prostatitis.

1980s. Launch of peptide biologic drugs

1980s. Launch of peptide biologic drugs

Launch of peptide biologic drugs portfolio which were developed in collaboration with Saint-Petersburg Military-Medicine Academy: Thymalin® and Samprost®.
Samson-Med product portfolio contained more than 40 units at that time.

1975-1980. Launch of Cytochrome-C and infusional form drugs

1975-1980. Launch of Cytochrome-C and infusional form drugs

Launch of Injectable Cytochrome-C developed in collaboration with Hematology and Transfusiology Research Institute.
Start of infusional forms production on base of blood substitutes production facilities.

1970s. Launch of blood substitutes production

1970s. Launch of blood substitutes production

Launch of plasma-substituting drugs portfolio developed in collaboration with Hematology and Transfusiology research institute.

1963. Chymopsin and Chymotrypsin production

1963. Chymopsin and Chymotrypsin production

Samson-Med launches production of Chymopsin and Chymotrypsin, which are still used in surgical and dental practices.

1941-1945. World War II

1941-1945. World War II

Samson-Med produces insulin and penicillin for military usage. The company was the first to introduce insulin production using ion-exchange resins.
During the war Samson-Med facilities had strategic importance for the army as it was the defence line of Leningrad city, and the highest point of the factory was an observation and coordination centre.

1937. Company Foundation

1937. Company Foundation

Samson-Med starts its history from enzyme manufacturing facility found in 1937 on the territory of meat processing plant. At the time of foundation, the company’s portfolio included basic endocrine-enzyme drugs: pepsin, hematogen, gastric acid.